Immunopositivity for Histone MacroH2A1 Isoforms Marks Steatosis-Associated Hepatocellular Carcinoma

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Rappa, Francesca ^a,b   Greco, Azzura ^c   Podrini, Christine ^c   Cappello, Francesco ^a,b,d   Foti, Michelangelo ^e   Bourgoin, Lucie ^e   Peyrou, Marion ^e   Marino, Arianna ^f   Scibetta, Nunzia ^g   Williams, Roger ^c   Mazzoccoli, Gianluigi ^h   Federici, Massimo ^f   Pazienza, Valerio ^h   Vinciguerra, Manlio ^b,c,i  

^a UNIVERSITY OF PALERMO   (Italy)

^b Euro Mediterranean Institute of Science and Technology   (Italy)

^c INSTITUTE OF HEPATOLOGY   (United Kingdom)

^d Department of Veterinary Medical Sciences   (Switzerland)

^e UNIVERSITY OF GENEVA   (Switzerland)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g Civic Hospital   (Italy)

^h CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLNITROSAMINE; HISTONE; HISTONE MACRO2A1.1; HISTONE MACRO2A1.2; ISOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIPID DIET; LIPID METABOLISM; LIVER CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; RISK FACTOR; STEATOSIS; UPREGULATION;

ANIMALS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CELL NUCLEUS; DIET, HIGH-FAT; DIETHYLNITROSAMINE; FATTY LIVER; GENE EXPRESSION REGULATION; HEPATOCYTES; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MICE; MICE, KNOCKOUT; PROTEIN ISOFORMS; PTEN PHOSPHOHYDROLASE; TUMOR MICROENVIRONMENT;

MURINAE; MUS;

EID: 84872808889     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054458     Document Type: Article

References (39)

1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ, (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625-1638.
2. Myers RP, (2009) Noninvasive diagnosis of nonalcoholic fatty liver disease. Ann Hepatol 8Suppl 1: S25-33.
3. Lou-Bonafonte JM, Arnal C, Osada J, (2011) New genes involved in hepatic steatosis. Curr Opin Lipidol 22: 159-164.
4. Kantartzis K, Schick F, Haring HU, Stefan N, (2010) Environmental and genetic determinants of fatty liver in humans. Dig Dis 28: 169-178.
5. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, et al. (2009) A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 16: 295-308.
6. He G, Karin M, (2011) NF-kappaB and STAT3- key players in liver inflammation and cancer. Cell Res 21: 159-168.
7. Mueller KM, Kornfeld JW, Friedbichler K, Blaas L, Egger G, et al. (2011) Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology 54: 1398-1409.
8. Park EJ, Lee JH, Yu GY, He G, Ali SR, et al. (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140: 197-208.
9. Das M, Garlick DS, Greiner DL, Davis RJ, (2011) The role of JNK in the development of hepatocellular carcinoma. Genes Dev 25: 634-645.
10. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, et al. (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317: 121-124.
11. Goldberg A, Allis CD, Bernstein E, (2007) Epigenetics: a landscape takes shape. Cell 128: 635-638.
12. Doye NC, An W, Angelov D, Bondarenko V, Mietton F, et al. (2006) Mechanism of polymerase II transcription repression by the histone variant macroH2A. Mol Cell Biol 26: 1156-1164.
13. Ladurner AG, (2003) Inactivating chromosomes: a macro domain that minimizes transcription. Mol Cell 12: 1-3.
14. Gamble M, Frizzell KM, Yang C, Krishnakumar R, Kraus WL, (2010) The histone variant macroH2A1 marks repressed autosomal chromatin, but protects a subset of its target genes from silencing. Genes Dev 24: 21-32.
15. Creppe C, Janich P, Cantarino N, Noguera M, Valero V, et al. (2012) MacroH2A1 regulates the balance between self-renewal and differentiation commitment in embryonic and adult stem cells. Mol Cell Biol 32: 1442-1452.
16. Boulard M, Storck S, Cong R, Pinto R, Delage,H,etal. (2010) Histone variant macroH2A1 deletion in mice causes female-specific steatosis. Epigenetics Chromatin 3: 8. [Epub ahead of print].
17. Changolkar L, Costanzi C, Leu NA, Chen D, McLaughlin KJ, et al. (2007) Developmental changes in histone macroH2A1-mediated gene regulation. Mol Cell Biol 27: 2758-2764.
18. Pogribny IP, Tryndyak VP, Bagnyukova TV, Melnyk S, Montgomery B, et al. (2009) Hepatic epigenetic phenotype predetermines individual susceptibility to hepatic steatosis in mice fed a lipogenic methyl-deficient diet. J Hepatol 51: 176-186.
19. Sporn JC, Kustatscher G, Hothorn T, Collado M, Serrano M, et al. (2009) Histone macroH2A isoforms predict the risk of lung cancer recurrence. Oncogene 28: 3423-3428.
20. Sporn JC, Jung B, (2012) Differential Regulation and Predictive Potential of MacroH2A1 Isoforms in Colon Cancer. Am J Pathol 180: 2516-2526.
21. Novikov L, Park JW, Chen H, Klerman H, Jalloh AS, et al. (2011) QKI-Mediated Alternative Splicing of the Histone Variant MacroH2A1 Regulates Cancer Cell Proliferation. Mol Cell Biol 31: 4244-4255.
22. Kapoor A, Goldberg MS, Cumberland LK, Ratnakumar K, Segura MF, et al. (2010) The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature 468: 1105-1109.
23. Vinciguerra M, Carrozzino F, Peyrou M, Carlone S, Montesano R, et al. (2009) Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN. J Hepatol 50: 1132-1141.
24. Vinciguerra M, Sgroi A, Veyrat-Durebex C, Rubbia-Brandt L, Buhler LH, et al. (2009) Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 49: 1176-1184.
25. Vinciguerra M, Veyrat-Durebex C, Moukil MA, Rubbia-Brandt L, Rohner-Jeanrenaud F, et al. (2008) PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. Gastroenterology 134: 268-280.
26. Vinciguerra M, Foti M, (2008) PTEN at the crossroad of metabolic diseases and cancer in the liver. Ann Hepatol 7: 192-199.
27. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, et al. (2004) Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113: 1774-1783.
28. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321.
29. Salamone F, Galvano F, Cappello F, Mangiameli A, Barbagallo I, et al. (2012) Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl Res 159: 477-486.
30. Farina F, Cappello F, Todaro M, Bucchieri F, Peri G, et al. (2000) Involvement of caspase-3 and GD3 ganglioside in ceramide-induced apoptosis in Farber disease. J Histochem Cytochem 48: 57-62.
31. Vinciguerra M, Foti M, (2006) PTEN and SHIP2 phosphoinositide phosphatases as negative regulators of insulin signalling. Arch Physiol Biochem 112: 89-104.
32. Pehrson JR, Fried VA, (1992) MacroH2A, a core histone containing a large nonhistone region. Science 257: 1398-1400.
33. Gamble MJ, Kraus WL (2010) Multiple facets of the unique histone variant macroH2A: From genomics to cell biology. Cell Cycle 9.
34. Kustatscher G, Hothorn M, Pugieux C, Scheffzek K, Ladurner AG, (2005) Splicing regulates NAD metabolite binding to histone macroH2A. Nat Struct Mol Biol 12: 624-625.
35. Feng GS, (2012) Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. Cancer Cell 21: 150-154.
36. Vinciguerra M, Fulco M, Ladurner A, Sartorelli V, Rosenthal N, (2010) SirT1 in muscle physiology and disease: lessons from mouse models. Dis Model Mech 3: 298-303.
37. Vinciguerra M, Santini MP, Martinez C, Pazienza V, Claycomb WC, et al. (2012) mIGF-1/JNK1/SirT1 signaling confers protection against oxidative stress in the heart. Aging Cell 11: 139-149.
38. Herranz D, Munoz-Martin M, Canamero M, Mulero F, Martinez-Pastor B, et al. (2010) Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun 1: 1-8.
39. Till S, Ladurner AG, (2009) Sensing NAD metabolites through macro domains. Front Biosci 14: 3246-3258.